• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
XL-765

XL-765

Product ID X4424
Cas No. 934493-76-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $147.20 Please Inquire
5 mg $249.80 Please Inquire
10 mg $405.20 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

XL-765 is an inhibitor of PI3K and mTOR that displays anticancer chemotherapeutic and anti-angiogenic activities; it is currently in clinical trials as a potential treatment for lymphomas and solid tumors. XL-765 inhibits cell proliferation, tumor growth, and angiogenesis in cellular and animal models of cancers.

Product Info

Cas No.

934493-76-2

Purity

≥98%

Formula

C13H14N6O

Formula Wt.

270.29

IUPAC Name

2-Amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one

Synonym

XL765, Voxtalisib, SAR245409

Solubility

DMSO 12 mg/mL (20.01 mM) Water Insoluble Ethanol Insoluble

Appearance

Light yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

X4424 MSDS PDF

Info Sheet

X4424 Info Sheet PDF

References

Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk Lymphoma. 2014 Nov 19:1-8. [Epub ahead of print] PMID: 25300944.

Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91. PMID: 24634413.

Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 May 1;20(9):2445-56. PMID: 24583798.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T7035

    Triptolide

    Diterpenoid epoxide found in Tripterygium.

    ≥98%
  • O9257

    16-Oxokahweol

    Synthetic kahweol derivative.

    ≥95%
  • P0346

    Palosuran Hydrochloride

    Urotensin II receptor antagonist.
  • C0153

    Calcitonin, rat

    Endogenous neuropeptide hormone, lowers extrace...

    ≥95%
  • I611325

    IPI-549

    Selective inhibitor of the γ isoform of PI3K (...

    ≥98%
  • N3276

    Nitroso(acetoxymethyl)methylamine

    NNK precursor found in tobacco smoke; carcinoge...

    ≥97%
  • V0245

    Valdecoxib

    NSAID; CB1 agonist, COX-2 inhibitor.

    ≥98%
  • T7031

    Triflumuron

    Insect growth regulator; chitin synthesis inhib...

    ≥98%
  • D1629

    Dehydroepiandrosterone

    Endogenous steroid hormone; ERβ, NMDA, σ1 ago...

    ≥98%
  • I5354

    Iniparib

    Cysteine adduct inducer, PARP-1 inhibitor.

    ≥98%
  • N0263

    Naphazoline Nitrate

    α1-adrenergic agonist.

    ≥97%
  • O7332

    OSI-027

    mTOR inhibitor.

    ≥99%
  • R2400

    RG-108

    DNMT inhibitor.

    ≥98%
  • E5214

    α-Endorphin

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • N7200

    NS-11394

    GABA-A α5/3/2 positive modulator.

    ≥98%
  • T7133

    Trimetazidine Dihydrochloride

    Long-chain 3-ketoacyl-CoA thiolase inhibitor, p...

    ≥99%
  • A4805

    Amastatin Hydrochloride Hydrate

    Aminopeptidase inhibitor.

    ≥98%
  • Z3444

    Zileuton

    5-Lipoxygenase inhibitor.

    ≥98%
  • M578522

    Monascin

    Fungal pigment found in red yeast rice

    ≥98%
  • L5750

    Lomeguatrib

    MGMT inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only